H.C. Wainwright reiterates Buy rating on Harrow Health stock, maintains $64 target

Harrow Health (HROW) is pursuing aggressive growth, targeting $250 million in quarterly revenue by Q4 2027, a significant increase from $63.7 million in Q2 2025, through new product launches, expanded access initiatives, and strategic acquisitions like Melt Pharmaceuticals. This strategy is bolstered by recent financing, including a $250 million senior unsecured notes offering, and has garnered strong analyst support, with H.C. Wainwright reiterating a Buy rating and $64 price target, and B.Riley raising its target to $70 while naming HROW a top idea for H2 2025.

Analysis

Harrow Health (HROW) has outlined an aggressive growth strategy, aiming to increase quarterly revenue to $250 million by Q4 2027, a substantial jump from the $63.7 million reported for Q2 2025. This plan is supported by a multi-pronged approach that includes expanding its VEVYE and Harrow Access for All programs, launching new products such as BYQLOVI in Q1 2026, and pursuing strategic acquisitions like Melt Pharmaceuticals. The company's historical performance, with a 47.69% revenue growth over the last twelve months, provides some precedent for this high-growth trajectory. To fund this expansion, Harrow has secured significant capital through a $250 million private offering of 8.625% senior unsecured notes and a new $40 million senior secured revolving credit facility. The strategy has garnered strong positive sentiment from analysts, with H.C. Wainwright reiterating a $64 price target and B.Riley raising its target to $70, designating the stock a top idea for the second half of 2025.

Key Decisions for Investors

• Investors should consider the company's clear and ambitious growth roadmap, targeting a near-quadrupling of quarterly revenue by 2027, which is strongly endorsed by analyst price targets of up to $76.
• Monitor the execution risks associated with this aggressive strategy, paying close attention to the sales trajectory of key products like VEVYE, the successful integration of acquisitions, and the progress of new product launches.
• Factor in the increased financial leverage from the $250 million note offering at a notable 8.625% interest rate, which, while funding growth, also elevates the company's risk profile and future interest expense obligations.